Report Overview
Premenstrual Syndrome (PMS) Treatment refers to the range of medical and lifestyle interventions aimed at alleviating the emotional, behavioral, and physical symptoms that occur in the luteal phase of the menstrual cycle, typically one to two weeks before menstruation. These symptoms, including mood swings, irritability, fatigue, bloating, and breast tenderness, affect millions of women globally and can significantly disrupt daily life.
Treatment modalities include medications such as antidepressants and hormonal therapies, dietary adjustments, psychotherapy, and alternative treatments like exercise and mindfulness.
The market encapsulates pharmaceutical drugs, over-thecounter solutions, supplements, and therapeutic counseling services specifically targeted toward PMS relief.
In 2023, the U.S. market stood as a significant contributor to global revenues, although precise figures are currently unavailable.
Market Analysis
The global Premenstrual Syndrome Treatment Market was valued at USD 1.9 billion in 2024 and is projected to reach approximately USD 3.1 billion by 2032. This growth represents a robust Compound Annual Growth Rate (CAGR) of 6.7% during the forecast period of 2024 to 2032.
The increase in awareness about PMS and the growing emphasis on women’s health are key contributors to the expanding market size.
Regional Analysis
North America
Europe
Asia-Pacific
South America
Middle East & Africa
Market Segmentation
Younger than 20 Years
20-40 Years Old Adults
